Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Great DSLR Cameras for Photography Devotees - 2'No Kings' protests recap: More than 8 million turned out across all 50 states, organizers say
- 3Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
- 4The 10 Most Noteworthy Games in History
- 5Disability rights activist and author Alice Wong dies at 51
- Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick
- Egypt's cafés and shops forced to close early due to Iran war
- HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
- 2026 will be the year NASA astronauts fly around the moon again — if all goes to plan
- Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
- I watched the buzzy new AI documentary — and left feeling both hopeful and terrified
- The risk of falling space junk hitting airplanes is on the rise, experts warn
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- 'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
